These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6605324)

  • 21. In vivo testing of a 2-nitroimidazole radiosensitizer (Ro 03-8799) using repeated administration.
    Williams MV; Denekamp J; Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):477-81. PubMed ID: 7107370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Newly synthesized hypoxia-mediated drugs as radiosensitizers and cytotoxic agents.
    Astor M; Hall EJ; Biaglow JE; Parham JC
    Int J Radiat Oncol Biol Phys; 1982 Jan; 8(1):75-83. PubMed ID: 7061257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electron-affinic radiosensitizers possessing NPSH-reactive side chains: cytotoxicity and radiosensitizing activity towards hypoxic EMT6 cells in vitro.
    Zhou L; Nishimoto S
    Int J Radiat Biol; 1995 Mar; 67(3):335-46. PubMed ID: 7897282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxic radiosensitizers: prospects for effective compounds with fewer toxic side-effects.
    Rupp WD; Mroczkowski Z; Agrawal KC
    Br J Cancer Suppl; 1978 Jun; 3():60-3. PubMed ID: 98175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing intracellular uptake and radiosensitization by 2-nitroimidazoles in vitro.
    Brown DM; Gonzalez-Mendez R; Brown JM
    Radiat Res; 1983 Mar; 93(3):492-505. PubMed ID: 6856754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-Chloro-4-nitroimidazole radiosensitizers of hypoxic tumor cells in vivo.
    Watras J; Wideł M; Suwiński J; Salwińska E
    Neoplasma; 1987; 34(3):253-9. PubMed ID: 3614461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials of radiosensitizers: what should we expect?
    Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined cytokinesis-block micronucleus and chromosomal aberration assay for the evaluation of radiosensitizers at low radiation doses.
    Oya N; Shibamoto Y; Shibata T; Sasai K; Sugiyama T; Abe M
    Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1153-9. PubMed ID: 7961025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiosensitization of hypoxic tumor cells by simultaneous administration of hyperthermia and nitroimidazoles.
    Hofer KG; Hofer MG; Ieracitano J; McLaughlin WH
    Radiat Res; 1977 May; 70(2):362-77. PubMed ID: 860011
    [No Abstract]   [Full Text] [Related]  

  • 30. Influence of tumour size on radiosensitization by misonidazole.
    Stanley JA; Peckham MJ; Steel GG
    Br J Cancer Suppl; 1978 Jun; 3():220-4. PubMed ID: 277232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of the effect of cytotoxic drugs by radiosensitizers.
    Martin WM; McNally NJ; De Ronde J
    Br J Cancer; 1981 Jun; 43(6):756-66. PubMed ID: 7248157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
    Sasai K; Nishimoto S; Shimokawa K; Hisanaga Y; Kitakabu Y; Shibamoto Y; Zhou L; Wang J; Takahashi M; Kagiya T
    Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1249-54. PubMed ID: 1828462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
    Perlman ME; Dunn JA; Piscitelli TA; Earle J; Rose WC; Wampler GL; MacDiarmid JE; Bardos TJ
    J Med Chem; 1991 Apr; 34(4):1400-7. PubMed ID: 2016716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
    Hei TK; Geard CR; Osmak RS; Hall EJ
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of artificial lung metastases by misonidazole.
    Rockwell S; Nierenburg M; Irvin CG
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1395-8. PubMed ID: 6469763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy.
    Yuhas JM; Yurconic M; Kligerman MM; West G; Peterson DF
    Radiat Res; 1977 May; 70(2):433-43. PubMed ID: 193145
    [No Abstract]   [Full Text] [Related]  

  • 38. Radiosensitizers: rationale and potential.
    Brown JM
    Cancer Treat Rep; 1981; 65 Suppl 2():95-102. PubMed ID: 7346152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
    Kanclerz A; Chapman JD
    Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains.
    Adams GE; Ahmed I; Clarke ED; O'Neill P; Parrick J; Stratford IJ; Wallace RG; Wardman P; Watts ME
    Int J Radiat Biol Relat Stud Phys Chem Med; 1980 Dec; 38(6):613-26. PubMed ID: 6970731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.